Explore
Novel Biomarkers of Gastrointestinal Cancer
0 Ungluers have
Faved this Work
Login to Fave
Gastrointestinal (GI) cancer is a major cause of morbidity and mortality in the world. Since early diagnosis and optimal treatment selection are crucial to improving the prognosis of these diseases, the discovery of useful biomarkers has the potential to greatly reduce their burden. Recent technical and mechanical developments have allowed for the detection of tiny differences in various factors modified in physical conditions, which could contribute to the discovery of novel biomarkers for some diseases.In this Special Issue, we aim to focus on novel biomarkers for GI cancers, including esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer and biliary cancer. In addition, any samples (tissue, blood, urine and feces) are useful as biomarker sources, although body-fluid-based biomarkers are promising as diagnostic biomarkers due to their noninvasiveness. This Special Issue aims to collect novel insights clarifying the current situation and future perspective in this field.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 45 times via unglue.it ebook links.
- 45 - pdf (CC BY) at Unglue.it.
Keywords
- 16S rRNA amplicon
- advanced adenoma
- advanced gastric cancer
- AFP
- artificial intelligence
- biomarker
- biomarkers
- cancer screening
- cancer screening tests
- chemoresistance
- circulating tumour cell (CTC)
- cirrhosis
- Clinical & internal medicine
- colorectal cancer
- colorectal neoplasms
- CXCR4
- Diseases & disorders
- early detection of cancer
- epigenetic regulation genes
- extracellular vesicles
- gastric cancer
- GSVA
- hepatocellular cancer
- hepatocellular carcinoma
- Liquid Biopsy
- liver fibrosis
- long non-coding RNA
- Machine learning
- MALDI-TOF
- medicine
- Metagenomics
- microbiome
- microRNA
- miR-129-1-3p
- miR-566
- molecular genetic markers
- mouse model
- mRNA
- n/a
- neoadjuvant chemoradiation
- oesophageal cancer
- oncology
- overall survival
- plasminogen activator inhibitor type 1 (PAI-1)
- precision medicine
- prognosis
- Proteomics
- rectal cancer
- recurrence
- screening
- serine proteases
- serpins
- SHG/TPEF microscopy
- somatic mutations
- stool
- targeted therapy
- tumour microenvironment
- unfolded protein
- unfolded protein score
- urinary miRNA
- urokinase plasminogen activator (uPA)
- urokinase plasminogen activator receptor (uPAR)
Links
DOI: 10.3390/books978-3-0365-4932-3Editions